C Lloret-Linares1, P Faucher, M Coupaye, R Alili, A Green, A Basdevant, K Clément, C Poitou. 1. 1] Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Unit of Therapeutic Research, Department of Internal Medicine, Paris, France [2] INSERM U705, CNRS UMR 8206, Neuropsychopharmacology of Drug Addiction, Faculty of Pharmacy, University Paris Descartes, Paris, France.
Abstract
CONTEXT: The care of patients with hypothalamic obesity is challenging. OBJECTIVE: To compare body composition, basal metabolic rate (BMR) and metabolic outcomes of adults, with lesional or genetic hypothalamic obesity, with obese patients suffering from primary obesity, once matched for body mass index (BMI). DESIGN AND PATIENTS: Adults with hypothalamic obesity of genetic origin (Prader Willi syndrome (PWS)) or acquired hypothalamic damage (HD), such as craniopharygioma, were compared with obese control candidates awaiting bariatric surgery (C), with a BMI between 35 and 65 kg m(-)(2), and aged between 18 and 50 years. MAIN OUTCOME MEASURES: Body composition measured by whole-body dual-energy X-ray absorptiometry scanning, BMR using indirect calorimetry, hormonal and metabolic assessments. RESULTS: A total of 27 adults with a genetic diagnosis of PWS, 15 obese subjects with HD and 206 obese controls with similar BMI were studied. Compared with the control group, PWS patients had an increased percentage of fat mass (FM), and a decreased percentage of android FM. The BMR of PWS patients was significantly lower than controls and highly correlated with lean body mass in PWS and C patients. Body composition of HD was similar with those of obese patients. A trend toward an increased prevalence of diabetes in HD patients and of cytolysis in PWS was observed in comparison with primary obese patients. CONCLUSION: Genetic and lesional hypothalamic obesities have different consequences for phenotypic features such as body composition or BMR compared with primary obese patients. The mechanisms of adipose tissue development and metabolic complications may be different between genetic and lesional obesities.
CONTEXT: The care of patients with hypothalamic obesity is challenging. OBJECTIVE: To compare body composition, basal metabolic rate (BMR) and metabolic outcomes of adults, with lesional or genetic hypothalamic obesity, with obesepatients suffering from primary obesity, once matched for body mass index (BMI). DESIGN AND PATIENTS: Adults with hypothalamic obesity of genetic origin (Prader Willi syndrome (PWS)) or acquired hypothalamic damage (HD), such as craniopharygioma, were compared with obese control candidates awaiting bariatric surgery (C), with a BMI between 35 and 65 kg m(-)(2), and aged between 18 and 50 years. MAIN OUTCOME MEASURES: Body composition measured by whole-body dual-energy X-ray absorptiometry scanning, BMR using indirect calorimetry, hormonal and metabolic assessments. RESULTS: A total of 27 adults with a genetic diagnosis of PWS, 15 obese subjects with HD and 206 obese controls with similar BMI were studied. Compared with the control group, PWSpatients had an increased percentage of fat mass (FM), and a decreased percentage of android FM. The BMR of PWSpatients was significantly lower than controls and highly correlated with lean body mass in PWS and C patients. Body composition of HD was similar with those of obesepatients. A trend toward an increased prevalence of diabetes in HDpatients and of cytolysis in PWS was observed in comparison with primary obesepatients. CONCLUSION: Genetic and lesional hypothalamic obesities have different consequences for phenotypic features such as body composition or BMR compared with primary obesepatients. The mechanisms of adipose tissue development and metabolic complications may be different between genetic and lesional obesities.
Authors: Maha Alsaif; Sarah A Elliot; Michelle L MacKenzie; Carla M Prado; Catherine J Field; Andrea M Haqq Journal: Adv Nutr Date: 2017-11-15 Impact factor: 8.701
Authors: Zainab Alyousif; Jennifer L Miller; Mariana Y Sandoval; Chad W MacPherson; Varuni Nagulesapillai; Wendy J Dahl Journal: Trials Date: 2018-04-27 Impact factor: 2.279
Authors: Susan G Woods; Allen Knehans; Sandra Arnold; Carol Dionne; Leah Hoffman; Peggy Turner; Jonathan Baldwin Journal: Food Nutr Res Date: 2018-06-18 Impact factor: 3.894
Authors: Lisa M Olsson; Christine Poitou; Valentina Tremaroli; Muriel Coupaye; Judith Aron-Wisnewsky; Fredrik Bäckhed; Karine Clément; Robert Caesar Journal: Gut Date: 2019-10-14 Impact factor: 23.059
Authors: G Muscogiuri; L Barrea; F Faggiano; M I Maiorino; M Parrillo; G Pugliese; R M Ruggeri; E Scarano; S Savastano; A Colao Journal: J Endocrinol Invest Date: 2021-04-23 Impact factor: 4.256